横浜市立大学大学院 医学研究科 幹細胞免疫制御内科学血液・リウマチ・感染症内科

MENU

業績

2020年

血液グループ

原著論文: 症例報告を含む

  1. Akahoshi Y, Igarashi A, Fukuda T, Uchida N, Tanaka M, Ozawa Y, Kanda Y, Onizuka M, Ichinohe T, Tanaka J, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of graft-versus-host disease and graft-versus-leukemia effect based on minimal residual disease in Philadelphia chromosome-positive acute lymphoblastic leukemia. Br J Haematol. 2020 Jul;190(1):84-92.
  2. Akahoshi Y, Nishiwaki S, Arai Y, Harada K, Najima Y, Kanda Y, Shono K, Ota S, Fukuda T, Uchida N, Shiratori S, Tanaka M, Tanaka J, Atsuta Y, Kako S. Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplant. 2020 Jul;55(7):1317-1325.
  3. Ando T, Fujisawa S, Teshigawara H, Matsumura A, Sakuma T, Suzuki T, Teranaka H, Ogusa E, Ishii Y, Miyashita K, Takahashi H, Nakajima Y, Miyazaki T, Hagihara M, Matsumoto K, Yamazaki E, Nakajima H. Computed Tomography-Defined Sarcopenia: Prognostic Predictor of Nonrelapse Mortality After Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Retrospective Study. Int J Hematol, 112; 46-56, 2020.
  4. Ando T, Suzuki T, Ishiyama Y, Koyama S, Tachibana T, Tanaka M, Kanamori H, Nakajima H: Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Analysis. Biol Blood Marrow Transplant, 26(1): 171-177, 2020.
  5. Ando T, Tachibana T, Tanaka M, Suzuki T, Ishiyama Y, Koyama S, Ogusa E, Numata A, Matsumoto K, Kanamori H, Nakajima H: Impact of graft sources on immune reconstitution and survival outcomes following allogeneic stem cell transplantation. Blood Adv, 4: 408-419, 2020.
  6. Arima N, Kanda J, Yabe T, Morishima Y, Tanaka J, Kako S, Sakaguchi H, Kato M, Ohashi K, Ozawa Y, Fukuda T, Ota S, Tachibana T, Onizuka M, Ichinohe T, Atsuta Y, Kanda Y. Increased Relapse Risk of Acute Lymphoid Leukemia in Homozygous HLA-C1 Patients after HLA-Matched Allogeneic Transplantation: A Japanese National Registry Study. Biol Blood Marrow Transplant, 26(3):431-437, 2020.
  7. Imahashi N, Terakura S, Kondo E, Kako S, Uchida N, Kobayashi H, Inamoto Y, Sakai H, Tanaka M, Ishikawa J, Kozai Y, Matsuoka KI, Kimura T, Fukuda T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation. Comparison of reduced-intensity/toxicity conditioning regimens for umbilical cord blood transplantation for lymphoid malignancies. Bone Marrow Transplant. 2020 Nov;55(11):2098-2108.
  8. Ishida T, Kimura H, Ozaki S, Kubo K, Sunami K, Takezako N, Fujita H, Hayashi T, Kiguchi T, Ohashi K, Yamamoto S, Takamatsu H, Kosugi H, Ohta K, Sakai R, Handa H, Kondo S, Abe Y, Omoto E, Mitani K, Morita S, Murakami H, Shimizu K: Continuous lenalidomide treatment after bortezomib-melphalan-prednisolone therapy for newly diagnosed multiple myeloma. Ann Hematol, 99(5): 1063-1072, 2020.
  9. Ito A, Kim SW, Matsuoka KI, Kawakita T, Tanaka T, Inamoto Y, Toubai T, Fujiwara SI, Fukaya M, Kondo T, Sugita J, Nara M, Katsuoka Y, Imai Y, Nakazawa H, Kawashima I, Sakai R, Ishii A, Onizuka M, Takemura T, Terakura S, Iida H, Nakamae M, Higuchi K, Tamura S, Yoshioka S, Togitani K, Kawano N, Suzuki R, Suzumiya J, Izutsu K, Teshima T, Fukuda T: Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study. Int J Hematol, 112(5): 674-689, 2020.
  10. Iwasaki H, Toda S, Murayama D, Takahashi H: Three Cases of Anaplastic Thyroid Carcinoma Transformation and Leukocytosis during Lenvatinib Treatment. Case Rep Endocrinol, 6667237. doi: 10.1155/2020/6667237. eCollection 2020.
  11. Fujita H, Ishikawa Y, Yokoyama Y: JSH practical guidelines for hematological malignancies, 2018: I. Leukemia-2. Acute promyelocytic leukemia (APL). Int J Hematol, 111(6): 747-760, 2020.
  12. Hino M, Matsumura I, Fujisawa S, Ishizawa K, Ono T, Sakaida E, Sekiguchi N, Tanetsugu Y, Fukuhara K, Ohkura M, Koide Y, Takahashi N: Phase 2 Study of Bosutinib in Japanese Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia. Int J Hematol, 112; 24-32, 2020.
  13. Kaito S, Nakajima Y, Hara K, Toya T, Nishida T, Uchida N, Mukae J, Fukuda T, Ozawa Y, Tanaka M, Ikegame K, Katayama Y, Kuriyama T, Kanda J, Atsuta Y, Ogata M, Taguchi A, Ohashi K. Heterogeneous impact of cytomegalovirus reactivation on nonrelapse mortality in hematopoietic stem cell transplantation. Blood Adv. 2020 Mar 24;4(6):1051-1061.
  14. Kaito S, Najima Y, Harada K, Fukuda T, Noguchi Y, Ikegame K, Tanaka M, Ozawa Y, Yoshida S, Sawa M, Ota S, Inoue Y, Tanaka J, Ichinohe T, Atsuta Y, Kako S; Adult Acute Lymphoblastic Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring t(1;19)(q23;p13.3); comparison with normal karyotype. Bone Marrow Transplant. 2020 Jul;55(7):1337-1346.
  15. Kako S, Kanda Y, Onizuka M, Aotsuka N, Usuki K, Tachibana T, Kobayashi T, Kato J, Yano S, Shimizu H, Shono K, Tanaka M, Tsukamoto S, Mori T, Yamazaki E, Najima Y, Hangaishi A, Hoshino T, Watanabe R, Matsumoto K, Okamoto S; for Kanto Study Group for Cell Therapy (KSGCT). Allogeneic hematopoietic stem cell transplantation for aplastic anemia with pre-transplant conditioning using fludarabine, reduced-dose cyclophosphamide, and low-dose thymoglobulin: A KSGCT prospective study. Am J Hematol, 95(3):251-257, 2020.
  16. Kanda J, Ando T, Kimura SI, Fujiwara SI, Imada K, Fujisawa S, Tachibana T, Atsuta Y, Kanda Y. Hematopoietic Stem Cell Transplantation From a Related Donor with Human Leukocyte Antigen 1-Antigen Mismatch in the Graft-Versus-Host Direction Using Low-dose Anti-thymocyte Globulin. Cell Transplant, 29: 1–12, 2020.
  17. Kanda Y, Kimura SI, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K: Japan Febrile Neutropenia Study Group. D-Index-Guided Early Antifungal Therapy Versus Empiric Antifungal Therapy for Persistent Febrile Neutropenia: A Randomized Controlled Noninferiority Trial. J Clin Oncol, 10; 38(8): 815-822, 2020.
  18. Kawashima N, Ishikawa Y, Atsuta Y, Sawa M, Ozawa Y, Hayashi M, Kohno A, Tomita A, Maeda T, Sakaida E, Usuki K, Hagihara M, Kanamori H, Matsuoka H, Kobayashi M, Asou N, Ohtake S, Matsumura I, Miyazaki Y, Naoe T, Kiyoi H; Japan Adult Leukemia Study Group (JALSG).: Allogeneic hematopoietic stem cell transplantation at the first remission for younger adults with FLT3-internal tandem duplication AML: The JALSG AML209-FLT3-SCT study. Cancer Sci. 2020 Jul;111(7):2472-2481. doi: 10.1111/cas.14448. Epub 2020 May 29.
  19. Kato H, Takahashi H, Sano K, Nakajima H: Corynebacterium bacteremia in patients with hematological malignancies and other medical conditions. Clinical Infection in Practice, 7–8: 100040, 2020.
  20. Kimura SI, Kanda Y, Iino M, Fukuda T, Sakaida E, Oyake T, Yamaguchi H, Fujiwara SI, Jo Y, Okamoto A, Fujita H, Takamatsu Y, Saburi Y, Matsumura I, Yamanouchi J, Shiratori S, Gotoh M, Nakamura S, Tamura K: Japan Febrile, Neutropenia Study Group. Efficacy and safety of micafungin in empiric and D-index-guided early antifungal therapy for febrile neutropenia; A subgroup analysis of the CEDMIC trial. Int J Infect Dis, 100: 292-297, 2020.
  21. Kimura SI, Fujita H, Handa H, Hiramoto N, Hosono N, Minamiguchi H, Takahashi T, Kato H, Ono T, Kanda Y, Kiyoi H, Matsumura I, Miyazaki Y: Japan Adult Leukemia Study Group (JALSG). Real-world management of infection during chemotherapy for acute leukemia in Japan: from the results of a nationwide questionnaire-based survey by the Japan Adult Leukemia Study Group. Int J Hematol, 112(3): 409-417, 2020.
  22. Konuma T, Kondo T, Mizuno S, Doki N, Aoki J, Fukuda T, Tanaka M, Sawa M, Katayama Y, Uchida N, Ozawa Y, Morishige S, Matsuoka KI, Ichinohe T, Onizuka M, Kanda J, Atsuta Y, Yanada M; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Conditioning Intensity for Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients with Poor-Prognosis Cytogenetics in First Complete Remission. Biol Blood Marrow Transplant. 2020 Mar;26(3):463-471.
  23. Kunimoto H, Fukuchi Y, Murakami K, Ikeda J, Teranaka H, Kato I, Miyazaki T, Enaka M, Mitsuhashi T, Yamazaki E, Kameyama K, Murata M, Okamoto S, Nakajima H: Establishment of a high-risk MDS/AML cell line YCU-AML1 and its xenograft model harboring t(3;3) and monosomy 7. HemaSphere, 4(5): e469, 2020.
  24. Kurosawa S, Shimomura Y, Tachibana T, Ishiyama K, Ota S, Kobayashi T, Uchida N, Fukushima K, Ashida T, Matsuoka KI, Kanda J, Ichinohe T, Atsuta Y, Murata M, Aoki J. Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant, 26(9):1607-1611, 2020.
  25. Kusumoto S, Tanaka Y, Suzuki R, Watanabe T, Nakata M, Sakai R, Fukushima N, Fukushima T, Moriuchi Y, Itoh K, Nosaka K, Choi I, Sawa M, Okamoto R, Tsujimura H, Uchida T, Suzuki S, Okamoto M, Takahashi T, Sugiura I, Onishi Y, Kohri M, Yoshida S, Kojima M, Takahashi H, Tomita A, Atsuta Y, Maruyama D, Tanaka E, Suzuki T, Kinoshita T, Ogura M, Ueda R, Mizokami M: Ultra-high sensitivity HBsAg assay can diagnose HBV reactivation following rituximab-based therapy in patients with lymphoma. J Hepatol, 73(2): 285-293, 2020.
  26. Matsumura A, Miyazaki T, Tachibana T, Ando T, Koyama M, Koyama S, Ishii Y, Takahashi H, Nakajima Y, Numata A, Yamamoto W, Motohashi K, Hagihara M, Matsumoto K, Fujisawa S, Nakajima H: Predictive values of early suppression of tumorigenicity 2 for acute GVHD and transplant-related complications after allogeneic stem cell transplantation: prospective observational study. Turk J Haematol, 20: 20-29, 2020.
  27. Minamiguchi H, Fujita F, Atsuta Y, Asou N, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Uchino Y, Tomita A, Tamaki S, Hagihara M, Fujimaki K, Yanada M, Maeda Y, Iwanaga M, Usui N, Kobayashi Y, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Naoe T, Akihiro A, Japan Adult Leukemia Study Group: Predictors of early death, serious hemorrhage, and differentiation syndrome in Japanese patients with acute promyelocytic leukemia. Ann Hematol, 99: 2787-2800, 2020.
  28. Miyao K, Terakura S, Kimura F, Konuma T, Miyamura K, Yanada M, Kako S, Morhishima S, Uchida N, Toya T, Ozawa Y, Fukuda T, Tanaka M, Sawa M, Takada S, Yoshida S, Kimura T, Ichinohe T, Atsuta Y, Kanda J; Donor/Source Working Group of the Japan Society for Hematopoietic Cell Transplantation. Updated Comparison of 7/8 HLA Allele-Matched Unrelated Bone Marrow Transplantation and Single-Unit Umbilical Cord Blood Transplantation as Alternative Donors in Adults with Acute Leukemia. Biol Blood Marrow Transplant. 2020 Nov;26(11):2105-2114.
  29. Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, Nishikori M, Ohata K, Sunami K, Yoshida I, Yamamoto G, Takahashi N, Okamoto M, Yano H, Nishimura Y, Tamaru S, Nishikawa M, Izutsu K, Kinoshita T, Suzumiya J, Ohshima K, Kato K, Katayama N, Yamaguchi M: DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase II study. Haematologica, 105(9): 2308-2315, 2020.
  30. Mori T, Saburi M, Hagihara M, Mori M, Yamazaki R, Kato J: Long-term remission of cryopyrin-associated periodic syndrome after allogeneic haematopoietic stem cell transplantation. Ann Rheum Dis. 2020 Nov 6: Online ahead of print.
  31. Nakajima H.: Molecular Pathogenesis and Treatment of Myelodysplastic Syndromes. Intern Med. 2021 Jan 1;60(1):15-23. doi: 10.2169/internalmedicine.4214-19. Epub 2020 Feb 1.
  32. Nakajima K, Kato H, Yamashiro T, Izumi T, Takeuchi I, Nakajima H, Utsunomiya D: COVID-19 Pneumonia: Infection Protection and Protocol at CT Suite. Jpn J Radiol. 2020 May;38(5):391-393
  33. Nagasawa R, Hara Y, Miyazaki T, Murohashi K, Watanabe H, Kaneko T: An autopsy case of ventilator-associated tracheobronchitis caused by Corynebacterium species complicated with diffuse alveolar damage. Respir Med Case Rep, 31: 101208, 2020.
  34. Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, Tachibana T, Fujisawa S, Nakajima Y, Numata A, Toyosaki M, Aoyama Y, Onizuka M, Hagihara M, Koyama S, Kanda Y, Nakasone H, Shimizu H, Kato S, Watanabe R, Shono K, Sakai R, Saito T, Nakaseko C, Okamoto S: A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort. Biol Blood Marrow Transplant, 26: 162-170, 2020.
  35. Sato E, Iriyama N, Tokuhira M, Takaku T, Ishikawa M, Nakazato T, Sugimoto KJ, Fujita H, Kimura Y, Fujioka I, Asou N, Komatsu N, Kizaki M, Hatta Y, Kawaguchi, T: The EUTOS long-term survival score predicts disease-specific mortality and molecular responses among patients with chronic myeloid leukemia in a practice-based cohort. Cancer Med, 9(23): 8931-8939, 2020.
  36. Suzuki M, Muroi A, Nojima M, Numata A, Takasaki H, Sakai R, Yokose T, Miyagi Y, Koshikawa N: Utility of a Reverse Phase Protein Array to Evaluate Multiple Biomarkers in Diffuse Large B-Cell Lymphoma. Proteomics Clin Appl, 14. E1900091, 2020.
  37. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Miyazaki T, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT): Clinical benefits of pre-conditioning intervention in patients with relapsed or refractory acute myeloid leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis. Biol Blood Marrow Transplant. 2020 Sep 29: S1083-8791(20)30619-4.
  38. Tachibana T, Kanda J, Ishizaki T, Najima Y, Tanaka M, Doki N, Fujiwara SI, Kimura SI, Onizuka M, Takahashi S, Saito T, Mori T, Fujisawa S, Sakaida E, Matsumoto K, Aotsuka N, Gotoh M, Watanabe R, Shono K, Usuki K, Tsukada N, Kanamori H, Kanda Y, Okamoto S; Kanto Study Group for Cell Therapy (KSGCT): Outcomes and prognostic factors for patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter analysis. Biol Blood Marrow Transplant, 26; 998-1004, 2020.
  39. Tachibana T, Ishizaki T, Takahashi S, Najima Y, Kimura SI, Sakaida E, Onizuka M, Mori T, Fujisawa S, Fujiwara SI, Saito T, Hagihara M, Aotsuka N, Gotoh M, Usuki K, Tsukada N, Kanda J, Kanamori H, Kanda Y, Okamoto S: Kanto Study Group for Cell Therapy (KSGCT):  Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplant, 55; 1497-1501, 2020.
  40. Tachibana T, Najima Y, Akahoshi Y, Hirabayashi S, Harada K, Doki N, Uchida N, Fukuda T, Sawa M, Ogata M, Takada S, Tanaka M, Matsuhashi Y, Tanaka J, Onizuka M, Ichinohe T, Atsuta Y, Kako S; Adult ALL Working Group of the Japan Society for Hematopoietic Cell Transplantation. The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. Ann Hematol, 99(10):2393-2404, 2020.
  41. Takeshita A, Asou N, Atsuta Y, Furumaki H, Sakura T, Ueda Y, Sawa M, Dobashi N, Taniguchi Y, Suzuki R, Nakagawa M, Tamaki S, Hagihara M, Fujimaki K, Minamiguchi H, Fujita H, Yanada M, Maeda Y, Usui N, Kobayashi Y, Kiyoi H, Ohtake S, Matsumura I, Naoe T, Miyazaki Y: The Japan Adult Leukemia Study Group. Impact of CD56 Continuously Recognizable as Prognostic Value of Acute Promyelocytic Leukemia: Results of Multivariate Analyses in the Japan Adult Leukemia Study Group (JALSG)-APL204 Study and a Review of the Literature. Cancers, 12: 1444, 2020.
  42. Tomita S, Kikuti Y, Carreras J, Sakai R, Takata K, Yoshino T, Bea S, Campo E, Missiaglia E, Bouilly J, Letourneau A, de Leval L, Nakamura N: Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma in Asia Frequently Shows SETD2 Alterations. Cancers (Basel), 12(12): 3539, 2020.
  43. Yamasaki S, Aoki J, Mori J, Mizuno S, Uchida N, Ohashi K, Fukuda T, Ikegame K, Eto T, Ogawa Y, Tanaka M, Hidaka M, Iwato K, Sawa M, Ichinohe T, Kanda Y, Atsuta Y, Yanada M, Yano S; Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Better disease control before allogeneic stem cell transplantation is crucial to improve the outcomes of transplantation for acute myeloid leukemia patients with extramedullary disease. Bone Marrow Transplant. 2020 Jan;55(1):249-252.
  44. Yamasaki S, Mori J, Kanda J, Imahashi N, Uchida N, Doki N, Tanaka M, Katayama Y, Eto T, Ozawa Y, Takada S, Onizuka M, Hino M, Kanda Y, Fukuda T, Atsuta Y, Yanada M. Effect of allogeneic HCT from unrelated donors in AML patients with intermediate- or poor-risk cytogenetics: a retrospective study from the Japanese Society for HCT. Ann Hematol. 2020 Dec;99(12):2927-2937.
  45. Yanada M, Konuma T, Yamasaki S, Kuwatsuka Y, Masuko M, Tanaka M, Ozawa Y, Toya T, Fukuda T, Ota S, Sawa M, Uchida N, Nakamae H, Eto T, Kanda J, Takanashi M, Kanda Y, Atsuta Y, Yano S. Time-Varying Effects of Graft Type on Outcomes for Patients with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 Feb;26(2):307-315.
  46. Yanada M, Takami A, Yamasaki S, Arai Y, Konuma T, Uchida N, Najima Y, Fukuda T, Tanaka M, Ozawa Y, Ikegame K, Takanashi M, Ichinohe T, Okamoto S, Atsuta Y, Yano S. Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. Ann Hematol. 2020 Jun;99(6):1351-1360.
  47. Yanada M, Fukuda T, Tanaka M, Ota S, Toya T, Mori T, Uchida N, Ozawa Y, Nakamae H, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Long-term results of reduced-intensity conditioning allogeneic hematopoietic cell transplantation for older patients with acute myeloid leukemia: a retrospective analysis of 10-year follow-up data. Bone Marrow Transplant. 2020 Oct;55(10):2008-2016.
  48. Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, Sawa M, Ozawa Y, Tanaka M, Uchida N, Nakamae H, Katayama Y, Matsuoka KI, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2020 Dec 2. Online ahead of print.
  49. Yokoyama H, Morishima Y, Fuji S, Uchida N, Takahashi S, Onizuka M, Tanaka M, Yuju O, Eto T, Ozawa Y, Takada S, Takanashi M, Kato K, Kanda Y, Ichinohe T, Atsuta Y, Kanda J; HLA Working Group of the Japan Society for Hematopoietic Cell Transplantation. Impact of HLA Allele Mismatch at HLA-A, -B, -C, and -DRB1 in Single Cord Blood Transplantation. Biol Blood Marrow Transplant. 2020 Mar;26(3):519-528.
  50. Yokoyama H, Takenaka K, Nishida T, Seo S, Shinohara A, Uchida N, Tanaka M, Takahashi S, Onizuka M, Kozai Y, Yasuhiro S, Ozawa Y, Katsuoka Y, Doki N, Sawa M, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H; Japan Society for Hematopoietic Cell Transplantation Transplantation-Related Complication Working Group. Favorable Effect of Cytomegalovirus Reactivation on Outcomes in Cord Blood Transplant and Its Differences Among Disease Risk or Type. Biol Blood Marrow Transplant. 2020 Jul;26(7):1363-1370.
  51. 中島秀明:骨髄異形成症候群の分子病態と治療.日本内科学会誌,109 , Suppl 号: 140b-141a,2020
  52. 中島秀明:造血器腫瘍学の基礎 2.発がんとがん抑制の分子機構(5)エピジェネティックス.日本臨床,78(3),2020
  53. 村田 明子, 川嶋 郁, 畠山 英司, 山崎 彩華, 松本 勝城, 深沢 貴志, 松本 菜月, 神谷 あかね, 藤田 浩之:擦式アルコール手指消毒薬の使用率向上による細菌分離率の低下. 日本環境感染学会誌, 35(4): 163-167, 2020.

総説

  1. Kunimoto H, Nakajima H: Clonal hematopoiesis: molecular basis and clinical relevance. Leuk Res, 98: 106457, 2020.
  2. 藤田 浩之: 真菌感染症の対策. 日本臨床, 78(3), 造血器腫瘍学(第2版)-基礎と臨床の最新研究動向: 276-282, 2020.

著書

  1. 藤澤 信: EBM血液疾患の治療2021-22.成人Ph陰性ALLの治療. 木崎昌弘、鈴木律朗、神田善伸、大森司、山﨑宏人 編, 中外医学社, 149-155, 2020.
  2. 泉 陽彦, 立花 崇孝, 高橋 寛行, 宮崎 拓也, 金森 平和, 田中 正嗣: Picture in Clinical Hematology No. 137,臨床血液,61(8), 855, 2020.
  3. 泉 陽彦, 立花 崇孝, 宮崎 拓也, 金森 平和, 為藤 葉子, 田中 正嗣: Picture in Clinical Hematology No. 139.臨床血液, 61(11), 1561, 2020.
  4. 立花崇孝:非寛解期AMLに対する同種移植の治療成績.血液内科. 81(6), 772-775, 2020.

検索 ページトップへ